One of our clients published preclinical data on NASH-fibrosis on Hepatology Communications
We announced that a study in the STAM™ mouse model of NASH performed by SMC Laboratories Inc. has been published in Hepatology Communications by Genomics Institute of the Novartis Research Foundation.:
Title: “Tropifexor-Mediated Abrogation of Steatohepatitis and Fibrosis is Associated with the Antioxidative Gene Expression Profile in Rodents”
Tropifexor, a novel nonbile acid FXR agonist, reversed established fibrosis and reduced the NAFLD Activity score and liver triglyceride in the STAM™ mouse model .
Please let me know if you would like further information on this publication or our NASH-HCC model.